ClinicalTrials.gg
CompletedNCT00195741Updated Feb 8, 2007

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

A Phase 3 interventional study of divalproex sodium in Migraine, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2007-02-08.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
159th of 609
300 · median 78
Started
2003
with 5 others
Phase 3
136 of 696
20 open now
Registered
13th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 159th largest by enrollment of the 609 interventional ones that give a count, is one of 6 that started in 2003, is one of 136 in phase 3, and was the 13th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Depakote ER is safe and effective in the reduction of occurrence of migraine headaches in adolescents.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Depakote ER
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject and subject's legal representative have voluntarily signed and dated an IRB-approved informed assent form and an IRB-approved form, respectively, before any study-specific procedures or tests are performed, including the discontinuation of any prohibited medications
  • Subject is male or a non-pregnant, non-lactating female;
  • Subject is between 12 and 17 years of age, inclusive, at randomization;
  • Subject weighs between 77 lbs (i.e., 35 kg) and 220 lbs (i.e., 100 kg) inclusive;
  • Subject currently has migraine headaches diagnosed according to the International Headache Society (IHS) diagnostic criteria occurring at an average frequency of at least 3, but no more than 12, migraine headaches per month during the 3 months prior to screening. Migraine headaches separated by a headache-free interval of \< 48 hours will be considered one migraine headache in assessing this criterion;
  • Subject's initial onset of migraine headache precedes the Screening Visit by at least 12 months;
  • Subject is judged to be in generally good health based on the results of a medical history, physical examination, 12-lead (ECG), and laboratory profile. When the Screening and Baseline Visits are combined as described in Section 5.1, continuing participation in the Baseline Phase will be contingent upon laboratory and ECG results. Any repeat laboratory testing must be completed in consultation with the Abbott Medical Monitor prior to randomization.

Experimental Phase

  • The following criteria define eligibility for subject enrollment in the

Experimental Phase and subsequent randomization and study drug assignment:

  • Subject experienced at least 3, but no more than 12, migraine headaches (separated by headache-free intervals of at least 48 hours), diagnosed according to the IHS diagnostic criteria,6 during the 4-week Baseline Phase of the study; and
  • Subject is still eligible for the study based on Baseline Phase inclusion criteria.

Exclusion criteria

Exclusion Criteria Baseline Phase

  • History of allergic reaction or significant sensitivity to valproate or similar drugs;
  • History of noncompliance with medication or medical instructions;
  • Previously randomized in this study;
  • Recent (previous 6 months) history of drug and/or alcohol abuse or has a positive urine drug screen, at the Screening Visit, for drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cocaine, opiates, and phencyclidine [PCP]);
  • Female, of , and not using an effective method of (e.g., total sexual abstinence or contraceptives);
  • History of cluster headaches (see Appendix G, Diagnostic Criteria for Headaches), seizure disorder, or suspected history of seizure disorder;
  • History of headaches of any type occurring on 15 or more days per month, on average, or uses medications excessively for headaches (e.g., regularly taking medication on more than 10 days per month);
  • Failed more than 2 adequate regimens of prophylactic antimigraine medications, including antiepilepsy drug(s) (e.g., gabapentin, topiramate) or 1 adequate regimen of valproate;
  • Use of any prophylactic antimigraine medication within a period equivalent to \< 5 half-lives of that medication before entering the Baseline Phase;
  • Daily use of any analgesic, ergotamine preparation, or nonsteroidal anti- inflammatory agent (see Appendix J, Examples of Prohibited Medications);
  • Use of the following medication classes or any specific drug listed below:

    • anticoagulants
    • antidepressants
    • antiepileptics
    • antipsychotics
    • benzodiazepines
    • beta-adrenergic blocking agents
    • calcium channel antagonists
    • cimetidine
    • cyproheptadine
    • erythromycin
    • ethosuximide
    • lithium salts
    • methysergide
    • phenobarbital
    • pemoline
    • rifampin
    • tolbutamide
    • or zidovudine
  • Use of valproate within 30 days prior to screening;
  • Use of aspirin and/or any aspirin-containing product (e.g., Excedrin Migraine, Pepto-Bismol, Alka Seltzer) within 5 half-lives prior to randomization or at any time during the Experimental Phase of the study;
  • Use of stimulants for Attention-Deficit Hyperactivity Disorder (ADHD) (with the exception of pemoline, Cylert) where a stable treatment regimen has not been established for a minimum of at least 2 months prior to screening or the treatment regimen that has been established is at risk of changing sometime during the trial;
  • Any serious medical or psychiatric disorder(s) that may confound the interpretation of the results from this study;
  • Central nervous system (CNS) neoplasm, CNS infection, demyelinating disease, degenerative neurological disease, or any progressive CNS disease;
  • History of encephalopathy, hepatitis, pancreatitis, or urea-cycle disorder or any underlying condition/disease, which might interfere with study drug absorption or completion of study drug therapy evaluation throughout the duration of the trial;
  • Screening laboratory results indicate the presence of surface antigen (HBSAG), or antibody or known history of any positive test result for ;
  • Screening laboratory results indicate: count \</= 100,000/uL or AST >/= 2 times (ULN);
  • Receipt of an drug within 30 days prior to study drug administration or scheduled to receive any other investigational drug anytime during the study; or
  • For any reason, subject is considered by the investigator to be an unsuitable candidate to receive Depakote or to participate in this study. Experimental Phase
  • Subjects exhibiting any of the following will be ineligible:
  • A positive pregnancy test result on Study Day 1;
  • Failure to properly maintain the Headache and Medication Diary, during the Baseline phase, to the extent that headache occurrences cannot be determined, due to noncompliance;
  • Excessive use of symptomatic medication(s) during the Baseline Phase (e.g., regularly taking medication on more than 10 days per month); or
  • Ineligibility for the study based on the Baseline Phase exclusion criteria.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction from baseline in 4-week migraine headache rate

Secondary outcomes

  1. Migraine headache rate in last 4 weeks of study

  2. Percent reduction from baseline

  3. Percent of subjects with > 75% reduction in migraine headache rate

07

Study locations

1 site
  • Global Medical Information - Abbott
    North Chicago, Illinois 60064, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195741
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
May 2003
Last update
Feb 8, 2007

Study contacts

Global Medical Information 800-633-9110
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion